• 1
    Vail DM, Young KM. Canine lymphoma and lymphoid leukemia. In: Withrow SJ, Vail DM, eds. Small Animal Clinical Oncology, 4th ed. St. Louis, MO: Saunders; 2007:699733.
  • 2
    Crivellari D, Lombardi D, Corona G, et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann Oncol 2006;17:807812.
  • 3
    Bertini M, Freilone R, Botto B, et al. Idarubicin in patients with diffuse large cell lymphomas: A randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Haematologica 1997;82:309313.
  • 4
    Zinzani PL, Martelli M, Storti S, et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995;19:329335.
  • 5
    Burton C, Smith P, Vaughan-Hudson G, et al. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol 2005;130:536541.
  • 6
    Mazue G, Iatropoulos M, Imondi A, et al. Anthracyclines: A review of general and special toxicity studies. Int J Oncol 1995;7:713726.
  • 7
    Reid JM, Pendergrass TW, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: A Childrens Cancer Study Group report. Cancer Res 1990;50:65256528.
  • 8
    Cook G, Clark RE, Morris TC, et al. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Br J Haematol 2004;126:792798.
  • 9
    Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:32673273.
  • 10
    Lofti K, Zackrisson A-L, Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett 2002;178:141149.
  • 11
    Owen L. TNM Classification of Tumors in Domestic Animals. Geneva: World Health Organization, 1980;4647.
  • 12
    Veterinary Co-operative Oncology Group. Common terminology criteria for adverse events following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Compar Oncol 2004;2:194213.
  • 13
    Vail DM. Cancer clinical trials: Development and implementation. Vet Clin North Am Small Anim Pract 2007;37:10331057.
  • 14
    Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: A brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997;35:8083.
  • 15
    Vail DM, Michels GM, Khanna C, et al. the Veterinary Co-operative Oncology Group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0). ‒ A Veterinary Co-operative Oncology Group (VCOG) Consensus Document. Vet Comp Oncol 2010;8:2837.
  • 16
    Idamycin PFS (Idarubicin hydrochloride injection) [package insert]. New York. Pharmacia and Upjohn Company. 2006.
  • 17
    Eksborg S, Björkholm M, Hast R, Fagerlund E. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite–a comparison of bolus versus 2 h infusion during a 3 day course. Anticancer Drugs 1997;8:4247.
  • 18
    Toffoli G, Sorio R, Aita P, et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Cancer Res 2000;6:22792287.
  • 19
    Moore AS, Ruslander D, Cotter SM, et al. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia. J Am Vet Med Assoc 1995;206:15501554.